Celvestrant 250mg Injection 1'S

INTRODUCTION

CELVESTRANT 250MG INJECTION contains Fulvestrant which belongs to the group of Estrogen blockers. It is used for a type of breast cancer called estrogen receptor positive breast cancer in postmenopausal women that is locally advanced or has spread to other parts of the body (metastatic). This medicine is also used with combination with palbociclib for women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, that is locally advanced or has spread to other parts of the body (metastatic). Women who have not reached menopause will also be treated with a medicine called a luteinizing hormone releasing hormone (LHRH) agonist.

CELVESTRANT 250MG INJECTION is not recommended to use in patients with severe liver problems. Before receiving CELVESTRANT 250MG INJECTION, inform your doctor if you have or ever had kidney problems, liver problems, osteoporosis, low number of platelets, bleeding problems, or previous problems with blood clots.

Avoid consumption of alcohol while receiving CELVESTRANT 250MG INJECTION, as it may lead to unwanted side effects. CELVESTRANT 250MG INJECTION is not recommended for use in pregnant and breastfeeding women. The most common side effects of receiving CELVESTRANT 250MG INJECTION are headache, vomiting, diarrhea, loss of appetite, urinary tract infection, back pain, vaginal bleeding, and thromboembolism. Consult your physician if any of the symptoms worsen or persists for a longer duration.

USES OF CELVESTRANT 250MG INJECTION

It is used for:

• a type of breast cancer called estrogen receptor positive breast cancer (in postmenopausal women)
• a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (in combination with other medicines)

HOW CELVESTRANT 250MG INJECTION WORKS

CELVESTRANT 250MG INJECTION blocks the action of estrogen on breast cancer cells which lowers the growth of some breast cancer cells that need estrogen to grow.

DIRECTIONS FOR USE

CELVESTRANT 250MG INJECTION will be administered by your doctor or nurse. The correct dose and duration will be decided by your doctor depending on your age, body weight, and disease condition.

SIDE EFFECTS OF CELVESTRANT 250MG INJECTION

HOW TO MANAGE SIDE EFFECTS

Diarrhea

Drink more fluids like water or fruit juice to keep yourself hydrated. Do not consume any medicine on your own without consulting your physician.

Nausea And Vomiting

Take this medicine with, or just after meals. Stick to simple meals. Avoid eating oily-rich or spicy foods.

WARNING & PRECAUTIONS

PREGNANCY

Contraindicated

CELVESTRANT 250MG INJECTION is not recommended for use in pregnant women. Consult your doctor for advice.

BREASTFEEDING

Contraindicated

CELVESTRANT 250MG INJECTION is not recommended for use in breastfeeding women as it may pass through breast milk. Consult your doctor for advice.

DRIVING AND USING MACHINES

Use with Caution

Do not drive or operate any machines if you feel tired after receiving CELVESTRANT 250MG INJECTION.

ALCOHOL

Consult your doctor

Avoid consumption of alcohol while receiving CELVESTRANT 250MG INJECTION. Consult your doctor for advice.

KIDNEY

Use with Caution

CELVESTRANT 250MG INJECTION should be used with caution in patients with kidney disease. Consult your doctor before receiving.

LIVER

Consult your doctor

CELVESTRANT 250MG INJECTION is not recommended for use in patients with serious liver problems and can be used with caution in patients with mild to moderate liver problems. Consult your doctor before receiving.

ALLERGY

Use with Caution

Do not receive CELVESTRANT 250MG INJECTION if you are allergic to Fulvestrant or any of the other ingredients of the medicine.

USE IN PEDIATRICS

Contraindicated

CELVESTRANT 250MG INJECTION is not recommended for use in children and adolescents (below the age of 18 years). Consult your doctor for advice.

USE IN GERIATRICS

Use with Caution

CELVESTRANT 250MG INJECTION should be used with caution in elder patients. Consult your doctor for advice.

INTERACTIONS

A. Drug-Drug interactions:

Before receiving CELVESTRANT 250MG INJECTION, inform your doctor if you are taking any of the following medicine:

• Anticoagulants (a medicine used to thin the blood clots) (Ex. warfarin)

Overdosage:

CELVESTRANT 250MG INJECTION will be administered to you only by a doctor or nurse in a hospital, so it is unlikely to receive an overdose. However, consult your physician or health care professionals if you experience any unusual symptoms.

SYNOPSIS

MORE INFORMATION

• Keep CELVESTRANT 250MG INJECTION out of reach of children
• Store at 2 to 8°C

FAQs ABOUT CELVESTRANT 250MG INJECTION

Q: How is CELVESTRANT 250MG INJECTION administered?

A: CELVESTRANT 250MG INJECTION will be given to you only by a doctor or nurse as a slow intramuscular administration. The correct dose and duration of CELVESTRANT 250MG INJECTION will be decided by your doctor depending on your age, body weight, and disease condition.

Q: Does CELVESTRANT 250MG INJECTION causes tiredness?

A: Tiredness is one of the most common side effects of CELVESTRANT 250MG INJECTION. However, it does not affect every individual. Consult your doctor immediately if you experience any unusual symptoms that occur after receiving CELVESTRANT 250MG INJECTION.

Q: Who should avoid administering CELVESTRANT 250MG INJECTION?

A: CELVESTRANT 250MG INJECTION is not recommended for patients having severe kidney problems, liver problems, bleeding disorders, osteoporosis, or previous problems with blood clots. Consult your doctor before receiving CELVESTRANT 250MG INJECTION.

Q: Is it safe to use CELVESTRANT 250MG INJECTION in pregnancy?

A: CELVESTRANT 250MG INJECTION is not recommended for use in pregnant women. Consult your doctor before receiving the medicine.

Q: Is there any food restriction before receiving CELVESTRANT 250MG INJECTION?

A: As such, there is no food restriction. Consult your doctor before receiving CELVESTRANT 250MG INJECTION.

REFERENCES

1. Claudine Isaacs, Anton Wellstein, and Anna T. Riegel. Hormones and Related Agents in Therapy of Cancer. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 13th Edition. New York McGraw Hill Medical 2018 Page – 1237-1247.

2. Mark R. Nathan and Peter Schmid. A Review of Fulvestrant in Breast Cancer. Journal of Oncology and Therapy. May 2017 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488136/

3. I. Blancas, C. Olier, V. Conde, J. L. Bayo, C. Herrero, I. Zarcos-Pedrinaci, F. Carabantes, J. M. Baena-Cañada, J. Cruz & M. Ruiz-Borrego. Real-world data of fulvestrant first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer. Journal of Nature. February 2021 https://www.nature.com/articles/s41598-021-83622-1

4. Katalin Boer. Fulvestrant in advanced breast cancer: evidence date and place in therapy. Journal of Therapeutic advances in medical oncology. June 2017 https://journals.sagepub.com/doi/10.1177/1758834017711097

5. AstraZeneca UK Limited. Electronic Medicines Compendium (EMC). [Revised in December 2020] [Accessed on 17th May] https://www.medicines.org.uk/emc/files/pil.68.pdf

AUTHOR DETAILS

Written By Dr. Janet.C, Pharm.D
Last updated on 03 Nov 2023 | 10:29 AM(IST)